An apparent danazol-induced primary hepatocellular carcinoma: case report.
This paper presents an apparent case of danazol-induced primary hepatocellular carcinoma in a 49-year-old patient, following two years of continuous therapy with this inhibitor of pituitary gonadotrophin. Discontinuation of the drug failed to cause regression of the tumour.
Buamah
P K
PK
D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000139:chemically induced*; D003613:Danazol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000139:chemically induced*; D008875:Middle Aged; D011245:Pregnadienes / Q000009:adverse effects*; D000509:alpha-Fetoproteins / Q000032:analysis
D011245:Pregnadienes; D000509:alpha-Fetoproteins; D003613:Danazol